Quinone methide bioactivation pathway: Contribution to toxicity and/or cytoprotection?

Current Organic Chemistry

Volumn 18, Issue 1, 2014, Pages 61-69

  Bolton, Judy Louise ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Bioactivation; P450; Quinone; Quinone methide; Selective estrogen receptor modulators (SERMs)

Indexed keywords

DETOXIFICATION; DRUG INTERACTIONS; GENE EXPRESSION; ISOMERIZATION; ISOMERS; OXIDATION; PHENOLS;

BIOACTIVATION; BIOACTIVATION PATHWAYS; CYTOPROTECTION; NATURAL PRODUCTS; O-QUINONES; OESTROGENS; P-QUINONE METHIDES; QUINONE METHIDE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

TOXICITY;

EID: 84892969293     PISSN: 13852728     EISSN: None     Source Type: Journal    
DOI: 10.2174/138527281801140121123046     Document Type: Article

References (114)

1. Leung, L.; Kalgutkar, A. S.; Obach, R. S.; Metabolic activation in druginduced liver injury. Drug Metab. Rev., 2012, 44, 18-33.
2. Thompson, D. C.; Thompson, J. A.; Sugumaran, M.; Moldeus, P.; Biological and toxicological consequences of quinone methide formation. Chem. Biol. Interact., 1993, 86, 129-162.
3. Peter, M. G.; Chemical Modifications of Bio-Polymers by Quinones and Quinone Methides. Angew. Chem. Int. Edit., 1989, 28, 555-570.
4. Monks, T. J.; Jones, D. C.; The metabolism and toxicity of quinones, quinonimines, quinone methides, and quinone-thioethers. Curr. Drug Metab., 2002, 3, 425-438.
5. Bolton, J. L.; Thompson, J. A.; (2009) Formation and Reactions of Xenobiotic Quinone Methides in Biology., in Reactive intermediates in chemistry and biology: Quinone methides (Rokita, S. E., Ed.) pp 329-356, Wiley.
6. Richard, J. P.; Toteva, M. M.; Crugeiras, J.; Structure-reactivity relationships and intrinsic reaction barriers for nucleophile additions to a quinone methide: A strongly resonance-stabilized carbocation. J. Am. Chem. Soc., 2000, 122, 1664-1674.
7. Gan, J.; Harper, T. W.; Hsueh, M. M.; Qu, Q.; Humphreys, W. G.; Dansyl glutathione as a trapping agent for the quantitative estimation and identification of reactive metabolites. Chem. Res. Toxicol., 2005, 18, 896-903.
8. Fujisawa, S.; Atsumi, T.; Kadoma, Y.; Sakagami, H.; Antioxidant and prooxidant action of eugenol-related compounds and their cytotoxicity. Toxicology, 2002, 177, 39-54.
9. Dufrasne, F.; Gelbcke, M.; Neve, J.; Kiss, R.; Kraus, J. L.; Quinone methides and their prodrugs: a subtle equilibrium between cancer promotion, prevention, and cure. Curr. Med. Chem., 2011, 18, 3995-4011.
10. Dowers, T. S.; Qin, Z. H.; Thatcher, G. R.; Bolton, J. L.; Bioactivation of selective estrogen receptor modulators (SERMs). Chem. Res. Toxicol., 2006, 19, 1125-1137.
11. Bolton, J. L.; Acay, N. M.; Vukomanovic, V.; Evidence that 4-allyl-oquinones spontaneously rearrange to their more electrophilic quinone methides: potential bioactivation mechanism for the hepatocarcinogen safrole. Chem. Res. Toxicol., 1994, 7, 443-450.
12. Iverson, S. L.; Hu, L. Q.; Vukomanovic, V.; Bolton, J. L.; The influence of the para-alkyl substituent on the isomerization of o-quinones to p-quinone methides: Potential bioactivation mechanism for catechols. Chem. Res. Toxicol., 1995, 8, 537-544.
13. Bolton, J. L.; Thatcher, G. R.; Potential mechanisms of estrogen quinone carcinogenesis. Chem. Res. Toxicol., 2008, 21, 93-101.
14. Rietjens, I. M.; Al Huseiny, W.; Boersma, M. G.; Flavonoids and alkenylbenzenes: New concepts in bioactivation studies. Chem. Biol. Interact., 2011, 192, 87-95.
15. Toteva, M. M.; Richard, J. P.; The generation and reactions of quinone methides. Adv. Phys. Org. Chem., 2011, 45, 39-91.
16. Driscoll, J. P.; Kornecki, K.; Wolkowski, J. P.; Chupak, L.; Kalgutkar, A. S.; O'Donnell, J. P.; Bioactivation of phencyclidine in rat and human liver microsomes and recombinant P450 2B enzymes: evidence for the formation of a novel quinone methide intermediate. Chem. Res. Toxicol., 2007, 20, 1488-1497.
17. Dunlap, T.; Chandrasena, R. E.; Wang, Z.; Sinha, V.; Thatcher, G. R.; Quinone formation as a chemoprevention strategy for hybrid drugs: balancing cytotoxicity and cytoprotection. Chem. Res. Toxicol., 2007, 20, 1903-1912.
18. Dunlap, T.; Abdul-Hay, S. O.; Chandrasena, R. E.; Hagos, G. K.; Sinha, V.; Wang, Z.; Wang, H.; Thatcher, G. R.; Nitrates and NO-NSAIDs in cancer chemoprevention and therapy: evidence querying the NO donor functionality. Nitric Oxide, 2008, 19, 115-124.
19. Dunlap, T.; Piyankarage, S. C.; Wijewickrama, G. T.; Abdul-Hay, S.; Vanni, M.; Litosh, V.; Luo, J.; Thatcher, G. R.; Quinone-induced activation of Keap1/Nrf2 signaling by aspirin prodrugs masquerading as nitric oxide. Chem. Res. Toxicol., 2012, 25, 2725-2736.
20. Yates, M. S.; Kensler, T. W.; Chemopreventive promise of targeting the Nrf2 pathway. Drug News Perspect., 2007, 20, 109-117.
21. Slocum, S. L.; Kensler, T. W.; Nrf2: control of sensitivity to carcinogens. Arch. Toxicol., 2011, 85, 273-284.
22. Turpaev, K. T.; Keap1-Nrf2 signaling pathway: mechanisms of regulation and role in protection of cells against toxicity caused by xenobiotics and electrophiles. Biochemistry (Mosc), 2013, 78, 111-126.
23. Holland, R.; Fishbein, J. C.; Chemistry of the cysteine sensors in Kelch-like ECH-associated protein 1. Antioxid. Redox Signal., 2010, 13, 1749-1761.
24. Walgren, J. L.; Mitchell, M. D.; Thompson, D. C.; Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit. Rev. Toxicol., 2005, 35, 325-361.
25. Patel, S. M.; Johnson, S.; Belknap, S. M.; Chan, J.; Sha, B. E.; Bennett, C.; Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J. Acquir. Immune Defic. Syndr., 2004, 35, 120-125.
26. Chen, J.; Mannargudi, B. M.; Xu, L.; Uetrecht, J.; Demonstration of the metabolic pathway responsible for nevirapine-induced skin rash. Chem. Res. Toxicol., 2008, 21, 1862-1870.
27. Popovic, M.; Shenton, J. M.; Chen, J.; Baban, A.; Tharmanathan, T.; Mannargudi, B.; Abdulla, D.; Uetrecht, J. P.; Nevirapine hypersensitivity. Handb. Exp. Pharmacol., 2010, 437-451.
28. Srivastava, A.; Lian, L. Y.; Maggs, J. L.; Chaponda, M.; Pirmohamed, M.; Williams, D. P.; Park, B. K.; Quantifying the metabolic activation of nevirapine in patients by integrated applications of NMR and mass spectrometries. Drug Metab. Dispos., 2010, 38, 122-132.
29. Sharma, A. M.; Li, Y.; Novalen, M.; Hayes, M. A.; Uetrecht, J.; Bioactivation of nevirapine to a reactive quinone methide: implications for liver injury. Chem. Res. Toxicol., 2012, 25, 1708-1719.
30. Watkins, P. B.; Whitcomb, R. W.; Hepatic dysfunction associated with troglitazone. N. Engl. J. Med., 1998, 338, 916-917.
31. Kassahun, K.; Pearson, P. G.; Tang, W.; McIntosh, I.; Leung, K.; Elmore, C.; Dean, D.; Wang, R.; Doss, G.; Baillie, T. A.; Studies on the metabolism of troglitazone to reactive intermediates and. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem. Res. Toxicol., 2001, 14, 62-70.
32. Fauman, B.; Aldinger, G.; Fauman, M.; Rosen, P.; Psychiatric sequelae of phencyclidine abuse. Clin. Toxicol., 1976, 9, 529-538.
33. Shebley, M.; Kent, U. M.; Ballou, D. P.; Hollenberg, P. F.; Mechanistic analysis of the inactivation of cytochrome P450 2B6 by phencyclidine: effects on substrate binding, electron transfer, and uncoupling. Drug Metab. Dispos., 2009, 37, 745-752.
34. Fisher, B.; Constantino, J. P.; Redmond, C. K.; Fisher, E. R.; Wickerham, D. L.; Cronin, W. M.; Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel project (NSABP) B-14. J. Natl. Cancer Inst., 1994, 86, 527-537.
35. Kim, S. Y.; Suzuki, N.; Laxmi, Y. R.; Shibutani, S.; Genotoxic mechanism of tamoxifen in developing endometrial cancer. Drug Metab. Rev., 2004, 36, 199-218.
36. Furr, B. a. J., VC; The phamacology and clinical uses of tamoxifen. Pharmacol. Ther., 1984, 25, 127-205.
37. Marques, M. M.; Beland, F. A.; Identification of tamoxifen-DNA adducts formed by 4-hydroxytamoxifen quinone methide. Carcinogenesis, 1997, 18, 1949-1954.
38. Fan, P. W.; Zhang, F.; Bolton, J. L.; 4-Hydroxylated metabolites of the antiestrogens tamoxifen and toremifene are metabolized to unusually stable quinone methides. Chem. Res. Toxicol., 2000, 13, 45-52.
39. McLuckie, K. I.; Routledge, M. N.; Brown, K.; Gaskell, M.; Farmer, P. B.; Roberts, G. C.; Martin, E. A.; DNA adducts formed from 4-hydroxytamoxifen are more mutagenic than those formed by alphaacetoxytamoxifen in a shuttle vector target gene replicated in human Ad293 cells. Biochemistry, 2002, 41, 8899-8906.
40. Shibutani, S.; Suzuki, N.; Terashima, I.; Sugarman, S.; Grollman, A.; Pearl, M.; Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen. Chem. Res. Toxicol., 1999, 12, 646-653.
41. Shibutani, S.; Ravindernath, A.; Suzuki, N.; Terashima, I.; Sugarman, S. M.; Grollman, A. P.; Pearl, M. L.; Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis, 2000, 21, 1461-1467.
42. Sridar, C.; D'Agostino, J.; Hollenberg, P. F.; Bioactivation of the cancer chemopreventive agent tamoxifen to quinone methides by cytochrome P4502B6 and identification of the modified residue on the apoprotein. Drug Metab. Dispos., 2012, 40, 2280-2288.
43. Sridar, C.; Kent, U. M.; Notley, L. M.; Gillam, E. M.; Hollenberg, P. F.; Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J. Pharmacol. Exp. Ther., 2002, 301, 945-952.
44. Yu, B.; Dietz, B. M.; Dunlap, T.; Kastrati, I.; Lantvit, D. D.; Overk, C. R.; Yao, P.; Qin, Z.; Bolton, J. L.; Thatcher, G. R.; Structural modulation of reactivity/activity in design of improved benzothiophene selective estrogen receptor modulators: induction of chemopreventive mechanisms. Mol. Cancer Ther., 2007, 6, 2418-2428.
45. Sripathy, S. P.; Chaplin, L. J.; Gaikwad, N. W.; Rogan, E. G.; Montano, M. M.; hPMC2 is required for recruiting an ERbeta coactivator complex to mediate transcriptional upregulation of NQO1 and protection against oxidative DNA damage by tamoxifen. Oncogene, 2008, 27, 6376-6384.
46. Hard, G.; Iatropoulos, M.; Jordan, K.; Radi, L.; Kaltenberg, O.; Imondi, A.; Williams, G.; Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl: CD(BR) rats. Cancer Research, 1993, 53, 4534-4541.
47. Liu, X.; Pisha, E.; Tonetti, D. A.; Yao, D.; Li, Y.; Yao, J.; Burdette, J. E.; Bolton, J. L.; Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites. Chem. Res. Toxicol., 2003, 16, 832-837.
48. Chen, Q.; Ngui, J. S.; Doss, G. A.; Wang, R. W.; Cai, X.; DiNinno, F. P.; Blizzard, T. A.; Hammond, M. L.; Stearns, R. A.; Evans, D. C.; Baillie, T. A.; Tang, W.; Cytochrome P450 3A4-Mediated Bioactivation of Raloxifene: Irreversible Enzyme Inhibition and Thiol Adduct Formation. Chem. Res. Toxicol., 2002, 15, 907-914.
49. Liu, H.; QIn, Z.; Thatcher, G. R.; Bolton, J. L.; Uterine peroxidase-catalyzed formation of diquinone methides from the selective estrogen receptor modulators raloxifene and desmethylated arzoxifene. Chem. Res. Toxicol., 2007, 20, 1676-1684.
50. VandenBrink, B. M.; Davis, J. A.; Pearson, J. T.; Foti, R. S.; Wienkers, L. C.; Rock, D. A.; Cytochrome P450 Architecture and Cysteine Nucleophile Placement Impact Raloxifene-Mediated Mechanism-Based Inactivation. Molecular Pharmacology, 2012, 82, 835-842.
51. Moore, C. D.; Reilly, C. A.; Yost, G. S.; CYP3A4-Mediated oxygenation versus dehydrogenation of raloxifene. Biochemistry, 2010, 49, 4466-4475.
52. Farley, J. F.; Blalock, S. J.; Trends and determinants of prescription medication use for treatment of osteoporosis. Am. J. Health Syst. Pharm., 2009, 66, 1191-1201.
53. Yu, L.; Liu, H.; Li, W.; Zhang, F.; Luckie, C.; van Breemen, R. B.; Thatcher, G. R.; Bolton, J. L.; Oxidation of raloxifene to quinoids: potential toxic pathways a diquinone methide and o-quinones. Chem. Res. Toxicol., 2004, 17, 879-888.
54. Pearson, J. T.; Wahlstrom, J. L.; Dickmann, L. J.; Kumar, S.; Halpert, J. R.; Wienkers, L. C.; Foti, R. S.; Rock, D. A.; Differential time-dependent inactivation of P450 3A4 and P450 3A5 by raloxifene: a key role for C239 in quenching reactive intermediates. Chem Res Toxicol, 2007, 20, 1778-1786.
55. Baer, B. R.; Wienkers, L. C.; Rock, D. A.; Time-dependent inactivation of P450 3A4 by raloxifene: identification of Cys239 as the site of apoprotein alkylation. Chem. Res. Toxicol., 2007, 20, 954-964.
56. Chen, Q.; Ngui, J. S.; Doss, G. A.; Wang, R. W.; Cai, X.; DiNinno, F. P.; Blizzard, T. A.; Hammond, M. L.; Stearns, R. A.; Evans, D. C.; Baillie, T. A.; Tang, W.; Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. Chem. Res. Toxicol., 2002, 15, 907-914.
57. Liu, H.; Liu, J.; van Breemen, R. B.; Thatcher, G. R.; Bolton, J. L.; Bioactivation of the selective estrogen receptor modulator desmethylated arzoxifene to quinoids: 4'-fluoro substitution prevents quinoid formation. Chem. Res. Toxicol., 2005, 18, 162-173.
58. Liu, H.; Qin, Z.; Thatcher, G. R.; Bolton, J. L.; Uterine peroxidase-catalyzed formation of diquinone methides from the selective estrogen receptor modulators raloxifene and desmethylated arzoxifene. Chem. Res. Toxicol., 2007, 20, 1676-1684.
59. Yager, J. D.; Davidson, N. E.; Estrogen carcinogenesis in breast cancer. N. Engl. J. Med., 2006, 354, 270-282.
60. Cavalieri, E.; Chakravarti, D.; Guttenplan, J.; Hart, E.; Ingle, J.; Jankowiak, R.; Muti, P.; Rogan, E.; Russo, J.; Santen, R.; Sutter, T.; Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim. Biophys. Acta, 2006, 1766, 63-78.
61. Cavalieri, E. L.; Rogan, E. G.; Unbalanced metabolism of endogenous estrogens in the etiology and prevention of human cancer. J. Steroid Biochem. Mol. Biol., 2011, 125, 169-180.
62. Bolton, J. L.; Shen, L.; p-Quinone methides are the major decomposition products of catechol estrogen o-quinones. Carcinogenesis, 1996, 17, 925-929.
63. Iverson, S. L.; Shen, L.; Anlar, N.; Bolton, J. L.; Bioactivation of estrone and its catechol metabolites to quinoid-glutathione conjugates in rat liver microsomes. Chem Res Toxicol, 1996, 9, 492-499.
64. Stack, D. E.; Byun, J.; Gross, M. L.; Rogan, E. G.; Cavalieri, E. L.; Molecular characteristics of catechol estrogen quinones in reactions with deoxyribonucleosides. Chem. Res. Toxicol., 1996, 9, 851-859.
65. Zhang, F.; Chen, Y.; Pisha, E.; Shen, L.; Xiong, Y.; van Breemen, R. B.; Bolton, J. L.; The major metabolite of equilin, 4-hydroxyequilin, autoxidizes to an o-quinone which isomerizes to the potent cytotoxin 4-hydroxyequilenin-o-quinone. Chem. Res. Toxicol., 1999, 12, 204-213.
66. Bolton, J. L.; Yu, L.; Thatcher, G. R.; Quinoids formed from estrogens and antiestrogens. Methods Enzymol., 2004, 378, 110-123.
67. Prokai-Tatrai, K.; Prokai, L.; Impact of metabolism on the safety of estrogen therapy. Ann. N Y Acad. Sci., 2005, 1052, 243-257.
68. Liehr, J. G.; Role of DNA adducts in hormonal carcinogenesis. Regul. Toxicol. Pharmacol., 2000, 32, 276-282.
69. Russo, J.; Russo, I. H.; Genotoxicity of steroidal estrogens. Trends Endocrinol. Metab., 2004, 15, 211-214.
70. Li, K. M.; Todorovic, R.; Devanesan, P.; Higginbotham, S.; Kofeler, H.; Ramanathan, R.; Gross, M. L.; Rogan, E. G.; Cavalieri, E. L.; Metabolism and DNA binding studies of 4-hydroxyestradiol and estradiol-3, 4-quinone and in female ACI rat mammary gland. Carcinogenesis, 2004, 25, 289-297.
71. Chakravarti, D.; Mailander, P. C.; Li, K. M.; Higginbotham, S.; Zhang, H. L.; Gross, M. L.; Meza, J. L.; Cavalieri, E. L.; Rogan, E. G.; Evidence that a burst of DNA depurination in SENCAR mouse skin induces error-prone repair and forms mutations in the H-ras gene. Oncogene, 2001, 20, 7945-7953.
72. Cavalieri, E.; Frenkel, K.; Liehr, J. G.; Rogan, E.; Roy, D.; Estrogens as endogenous genotoxic agents-DNA adducts and mutations. J. Natl. Cancer Inst. Monogr., 2000, 27, 75-93.
73. Saeed, M.; Rogan, E.; Fernandez, S. V.; Sheriff, F.; Russo, J.; Cavalieri, E.; Formation of depurinating N3Adenine and N7Guanine adducts by MCF-10F cells cultured in the presence of 4-hydroxyestradiol. Int. J. Cancer, 2007, 120, 1821-1824.
74. Zahid, M.; Kohli, E.; Saeed, M.; Rogan, E.; Cavalieri, E.; The greater reactivity of estradiol-3, 4-quinone vs estradiol-2, 3-quinone with DNA in the formation of depurinating adducts: Implications for tumor-initiating activity. Chem. Res. Toxicol., 2006, 19, 164-172.
75. Debrauwer, L.; Rathahao, E.; Jouanin, I.; Paris, A.; Clodic, G.; Molines, H.; Convert, O.; Fournier, F.; Tabet, J. C.; Investigation of the regio-and stereoselectivity of deoxyguanosine linkage to deuterated 2-hydroxyestradiol by using liquid chromatography/ESI-ion trap mass spectrometry. J. Am. Soc. Mass Spectrom., 2003, 14, 364-372.
76. Hayashi, N.; Hasegawa, K.; Barrett, J. C.; Tsutsui, T.; Estrogen-induced cell transformation and DNA adduct formation in cultured Syrian hamster embryo cells. Mol. Carcinogenesis, 1996, 16, 149-156.
77. Embrechts, J.; Lemiere, F.; Dongen, W. V.; Esmans, E. L.; Buytaert, P.; van Marck, E.; Kockx, M.; Makar, A.; Detection of estrogen DNA-adducts in human breast tumor tissue and healthy tissue by combined nano LC-nano ES tandem mass spectrometry. J. Am. Soc. Mass Spectrom., 2003, 14, 482-491.
78. Terashima, I.; Suzuki, N.; Shibutani, S.; Mutagenic properties of estrogen quinone-derived DNA adducts in simian kidney cells. Biochemistry, 2001, 40, 166-172.
79. Sumi, D.; Numasawa, Y.; Endo, A.; Iwamoto, N.; Kumagai, Y.; Catechol estrogens mediated activation of Nrf2 through covalent modification of its quinone metabolite to Keap1. J. Toxicol. Sci., 2009, 34, 627-635.
80. Lee, J. M.; Anderson, P. C.; Padgitt, J. K.; Hanson, J. M.; Waters, C. M.; Johnson, J. A.; Nrf2, not the estrogen receptor, mediates catechol estrogeninduced activation of the antioxidant responsive element. Biochim. Biophys. Acta., 2003, 1629, 92-101.
81. Pramod, K.; Ansari, S. H.; Ali, J.; Eugenol: a natural compound with versatile pharmacological actions. Nat. Prod. Commun., 2010, 5, 1999-2006.
82. Atsumi, T.; Fujisawa, S.; Tonosaki, K.; A comparative study of the antioxidant/prooxidant activities of eugenol and isoeugenol with various concentrations and oxidation. conditions. Toxicol. In Vitro, 2005, 19, 1025-1033.
83. Han, E. H.; Hwang, Y. P.; Jeong, T. C.; Lee, S. S.; Shin, J. G.; Jeong, H. G.; Eugenol inhibit 7, 12-dimethylbenz[a]anthracene-induced genotoxicity in MCF-7 cells: Bifunctional effects on CYP1 and NAD(P)H: quinone oxidoreductase. FEBS Lett., 2007, 581, 749-756.
84. Kumaravelu, P.; Dakshinamoorthy, D. P.; Subramaniam, S.; Devaraj, H.; Devaraj, N. S.; Effect of eugenol on drug-metabolizing enzymes of carbon tetrachloride-intoxicated rat liver. Biochem. Pharmacol., 1995, 49, 1703-1707.
85. Aggarwal, B. B.; Shishodia, S.; Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol., 2006, 71, 1397-1421.
86. Bodell, W. J.; Ye, Q.; Pathak, D. N.; Pongracz, K.; Oxidation of eugenol to form DNA adducts and 8-hydroxy-2'-deoxyguanosine: Role of quinone methide derviative in DNA adduct formation. Carcinogenesis, 1998, 19, 437-443.
87. Gannett, P. M.; Iversen, P.; Lawson, T.; The mechanism of inhibition of cytochrome P4502E1 by dihydrocapsaicin. Bioorg. Chem., 1990, 18, 185-198.
88. Lawson, T.; Gannett, P.; The mutagenicity of capsaicin and dihydrocapsaicin in V79 cells. Cancer Letters, 1989, 48, 109-113.
89. Reilly, C. A.; Henion, F.; Bugni, T. S.; Ethirajan, M.; Stockmann, C.; Pramanik, K. C.; Srivastava, S. K.; Yost, G. S.; Reactive Intermediates Produced from the Metabolism of the Vanilloid Ring of Capsaicinoids by P450 Enzymes. Chem. Res. Toxicol., 2013, 26, 55-66.
90. Bley, K.; Boorman, G.; Mohammad, B.; McKenzie, D.; Babbar, S.; A comprehensive review of the carcinogenic and anticarcinogenic potential of capsaicin. Toxicol. Pathol., 2012, 40, 847-873.
91. Aggarwal, B. B.; Kunnumakkara, A. B.; Harikumar, K. B.; Tharakan, S. T.; Sung, B.; Anand, P.; Potential of spice-derived phytochemicals for cancer prevention. Planta Med., 2008, 74, 1560-1569.
92. Joung, E. J.; Li, M. H.; Lee, H. G.; Somparn, N.; Jung, Y. S.; Na, H. K.; Kim, S. H.; Cha, Y. N.; Surh, Y. J.; Capsaicin induces heme oxygenase-1 expression in HepG2 cells via activation of PI3K-Nrf2 signaling: NAD(P)H: quinone oxidoreductase as a potential target. Antioxid. Redox Signal., 2007, 9, 2087-2098.
93. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin. Int. J. Toxicol., 2007, 26 Suppl 1, 3-106.
94. Chen, X. W.; Serag, E. S.; Sneed, K. B.; Zhou, S. F.; Herbal bioactivation, molecular targets and the toxicity relevance. Chem. Biol. Interact., 2011, 192, 161-176.
95. Zhou, S. F.; Xue, C. C.; Yu, X. Q.; Wang, G.; Metabolic activation of herbal and dietary constituents and its clinical and toxicological implications: an update. Curr. Drug Metab., 2007, 8, 526-553.
96. Paranjpe, R.; Gundala, S. R.; Lakshminarayana, N.; Sagwal, A.; Asif, G.; Pandey, A.; Aneja, R.; Piper betel leaf extract: anticancer benefits and bioguided fractionation to identify active principles for prostate cancer management. Carcinogenesis, 2013, 34, 1558-1566.
97. International Agency for Research on Cancer: Betel-quid and areca nut chewing. IARC Monograph, 1985, 37, 141-291.
98. Benedetti, M. S.; Malnoe, A.; Broillet, A. L.; Absorption, metabolism and excretion of safrole in the rat and man. Toxicology, 1977, 7, 69-83.
99. Sakano, K.; Inagaki, Y.; Oikawa, S.; Hiraku, Y.; Kawanishi, S.; Coppermediated oxidative DNA damage induced by eugenol: possible involvement of O-demethylation. Mutat. Res., 2004, 565, 35-44.
100. Chen, C. L.; Chi, C. W.; Chang, K. W.; Liu, T. Y.; Safrole-like DNA adducts in oral tissue from oral cancer patients with a betel quid chewing history. Carcinogenesis, 1999, 20, 2331-2334.
101. Chung, Y. T.; Hsieh, L. L.; Chen, I. H.; Liao, C. T.; Liou, S. H.; Chi, C. W.; Ueng, Y. F.; Liu, T. Y.; Sulfotransferase 1A1 haplotypes associated with oral squamous cell carcinoma susceptibility in male Taiwanese. Carcinogenesis, 2009, 30, 286-294.
102. Azuine, M. A.; Amonkar, A. J.; Bhide, S. V.; Chemopreventive efficacy of betel leaf extract and its constituents on 7, 12-dimethylbenz(a)anthracene induced carcinogenesis and their effect on drug detoxification system in mouse skin. Indian J. Exp. Biol., 1991, 29, 346-351.
103. Rietjens, I. M.; Boersma, M. G.; van der Woude, H.; Jeurissen, S. M.; Schutte, M. E.; Alink, G. M.; Flavonoids and alkenylbenzenes: mechanisms of mutagenic action and carcinogenic risk. Mutat. Res., 2005, 574, 124-138.
104. MacGregor, J. T.; Jurd, L.; Mutagenicity of plant flavonoids: structural requirements for mutagenic activity in Salmonella typhimurium. Mutat. Res., 1978, 54, 297-309.
105. Brown, J. P.; A review of the genetic effects of naturally occurring flavonoids, anthraquinolines and related compounds. Mutat. Res., 1980, 75, 243-277.
106. Boersma, M. G.; Vervoort, J.; Szymusiak, H.; Lemanska, K.; Tyrakowska, B.; Cenas, N.; Segura-Aguilar, J.; Rietjens, I. M.; Regioselectivity and reversibility of the glutathione conjugation of quercetin quinone methide. Chem. Res. Toxicol., 2000, 13, 185-191.
107. Williamson, G.; Plumb, G. W.; Uda, Y.; Price, K. R.; Rhodes, M. J. C.; Dietary quercetin glycosides: antioxidant activity and induction of the anticarcinogenic phase II marker enzyme quinone reductase in Hepalclc7 cells. Carcinogenesis, 1996, 17, 2385-2387.
108. Lee-Hilz, Y. Y.; Boerboom, A. M.; Westphal, A. H.; Berkel, W. J.; Aarts, J. M.; Rietjens, I. M.; Pro-oxidant activity of flavonoids induces EpREmediated gene expression. Chem. Res. Toxicol., 2006, 19, 1499-1505.
109. Walle, T.; Vincent, T. S.; Walle, U. K.; Evidence of covalent binding of the dietary flavonoid quercetin to DNA and protein in human intestinal and hepatic cells. Biochem. Pharmacol., 2003, 65, 1603-1610.
110. Beekmann, K.; Actis-Goretta, L.; van Bladeren, P. J.; Dionisi, F.; Destaillats, F.; Rietjens, I. M.; A state-of-the-art overview of the effect of metabolic conjugation on the biological activity of flavonoids. Food Funct., 2012, 3, 1008-1018.
111. Salminen, A.; Lehtonen, M.; Paimela, T.; Kaarniranta, K.; Celastrol: Molecular targets of Thunder God Vine. Biochem. Biophys. Res. Commun., 2010, 394, 439-442.
112. Wong, K. F.; Yuan, Y.; Luk, J. M.; Tripterygium wilfordii bioactive compounds as anticancer and anti-inflammatory agents. Clin. Exp. Pharmacol. Physiol., 2012, 39, 311-320.
113. Petronelli, A.; Pannitteri, G.; Testa, U.; Triterpenoids as new promising anticancer drugs. Anticancer Drugs, 2009, 20, 880-892.
114. Seo, W. Y.; Goh, A. R.; Ju, S. M.; Song, H. Y.; Kwon, D. J.; Jun, J. G.; Kim, B. C.; Choi, S. Y.; Park, J.; Celastrol induces expression of heme oxygenase-1 through ROS/Nrf2/ARE signaling in the HaCaT cells. Biochem. Biophys. Res. Commun., 2011, 407, 535-540.